Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial

被引:298
作者
Engstrom, Mats [1 ]
Berg, Thomas
Stjernquist-Desatnik, Anna [2 ]
Axelsson, Sara [2 ]
Pitkaranta, Anne [3 ]
Hultcrantz, Malou [4 ]
Kanerva, Mervi [3 ]
Hanner, Per [5 ]
Jonsson, Lars
机构
[1] Univ Uppsala Hosp, Akad Sjukhuset, Dept Otorhinolaryngol & Head & Neck Surg, SE-75185 Uppsala, Sweden
[2] Univ Lund Hosp, Dept Otorhinolaryngol & Head & Neck Surg, S-22185 Lund, Sweden
[3] Univ Helsinki, Cent Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Helsinki, Finland
[4] Karolinska Univ Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Stockholm, Sweden
[5] Sahlgrens Univ Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Gothenburg, Sweden
关键词
D O I
10.1016/S1474-4422(08)70221-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Previous trials of corticosteroid or antiviral treatments for Bell's palsy have been underpowered or have had insufficient follow-up. The aim of this study was to compare the short-term and long-term effects of prednisolone and valaciclovir in the recovery of the affected facial nerve in a large number of patients. Methods In this randomised, double-blind, placebo-controlled, multicentre trial, patients aged 18 to 75 years who sought care directly or were referred from emergency departments or general practitioners within 72 h of onset of acute, unilateral, peripheral facial palsy, between May, 2001, and September, 2006, were assessed. Patients were randomly assigned in permuted blocks of eight to receive placebo plus placebo; 60 mg prednisolone per day for 5 days then reduced by 10 mg per day (for a total treatment time of 10 days) plus placebo; 1000 mg valaciclovir three times per day for 7 days plus placebo; or prednisolone (10 days) plus valaciclovir (7 days). Follow-up was for 12 months. The primary outcome event was time to complete recovery of facial function, as assessed with a regional Sunnybrook scale score of 100 points. Analysis was by modified intention to treat. This study is registered with ClinicalTrials.gov, number NCT00510263. Findings Of 839 patients who were randomly assigned, 829 were included in the modified intention-to-treat analysis: 206 received placebo plus placebo, 210 prednisolone plus placebo, 207 valaciclovir plus placebo, and 206 prednisolone plus valaciclovir. Time to recovery was significantly shorter in the 416 patients who received prednisolone compared with the 413 patients who did not (hazard ratio 1.40, 95% CI 1.18 to 1.64; p<0.0001). There was no difference in time to recovery between the 413 patients treated with valaciclovir and the 416 patients who did not receive valaciclovir (1.01, 0.85 to 1.19; p=0.90). The number of patients with adverse events was similar in all treatment arms. Interpretation Prednisolone shortened the time to complete recovery in patients with Bell's palsy, whereas valaciclovir did not affect facial recovery.
引用
收藏
页码:993 / 1000
页数:8
相关论文
共 33 条
[1]   HERPES-SIMPLEX VIRUS IN IDIOPATHIC FACIAL PARALYSIS (BELL PALSY) [J].
ADOUR, KK ;
BELL, DN ;
HILSINGER, RL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1975, 233 (06) :527-530
[2]   Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: A double-blind, randomized, controlled trial [J].
Adour, KK ;
Ruboyianes, JM ;
Trent, CS ;
VonDoersten, PG ;
Quesenberry, CP ;
Byl, FM ;
Hitchcock, T .
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 1996, 105 (05) :371-378
[3]  
ALLEN D, 2004, COCHRANE DB SYST REV, V1
[4]   The revised CONSORT statement for reporting randomized trials: Explanation and elaboration [J].
Altman, DG ;
Schulz, KF ;
Moher, D ;
Egger, M ;
Davidoff, F ;
Elbourne, D ;
Gotzsche, PC ;
Lang, T .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (08) :663-694
[5]  
ANTUNES ML, 2000, ACTA AWHO, V19, P68
[6]   Idiopathic facial paralysis:: A randomized, prospective, and controlled study using single-dose prednisone versus acyclovir three times daily [J].
De Diego, JI ;
Prim, MP ;
De Sarriá, MJ ;
Madero, R ;
Gavilán, J .
LARYNGOSCOPE, 1998, 108 (04) :573-575
[7]  
ENGSTROM M, 1993, ARCH OTOLARYNGOL, V119, P221
[8]  
FISCH U, 1972, ARCHIV OTOLARYNGOL, V95, P335
[9]  
Furuta Y, 1997, J MED VIROL, V52, P316, DOI 10.1002/(SICI)1096-9071(199707)52:3&lt
[10]  
316::AID-JMV13&gt